AARTI DRUGS LTD. - 524348 - Notice Of 35Th Annual General Meeting
This is to inform you that 35th Annual General Meeting (''AGM'') of the Company is scheduled to be held on Tuesday, August 25, 2020 at 11.30 AM IST through Video Conferencing (''VC'') /Other Audio Visual Means (''OAVM'')
Aarti Drugs' API business gains as pharma firms diversify raw material sourcing from China
Company's stock among those that gained substantially during COVID-19 days. Drug maker planning contract manufacturing of specialty products. Other Indian pharma companies also benefit as buyers, both domestic and global, scout for non-Chinese suppliers of raw materials.
Buy Aarti Drugs; target of Rs 2090: Anand Rathi
Anand Rathi is bullish on Aarti Drugs has recommended buy rating on the stock with a target price of Rs 2090 in its research report dated July 28, 2020. AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to the applicable provisions of the SEBI Listing Regulations, we enclose the copies of newspaper advertisement published in Financial Express and Apla Mahanagar (Marathi), in compliance with the Ministry of Corporate Affairs Circular No. 20/2020 dated May 5, 2020, intimating inter-alia that 35th Annual General Meeting of the Company will be held on Tuesday, August 25, 2020 at 11:30 AM IST through Video Conferencing (VC) / Other Audio Visual Means (OAVM). AARTI DRUGS LTD. - 524348 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Please find enclosed herewith the Revised Annual Secretarial Compliance Report of the Company issued by M/s. Sunil M. Dedhia & Co., Company Secretaries in Practice, for the financial year ended March 31, 2020. AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find attached herewith press release on the Financial Results for the quarter ended June 30, 2020.
Earnings Call Transcript - Q1FY21 for Aarti Drugs
Conference Call with Aarti Drugs Management and Analysts on Q1FY21 Performance and Outlook. Listen to the full earnings transcript. AARTI DRUGS LTD. - 524348 - Audited Standalone And Consolidated Financial Results For The Quarter Ended June 30, 2020
We wish to inform you that Board of Directors at its Meeting held on Saturday, July 25, 2020, approved the Audited Standalone and Consolidated Financial Results for the Quarter ended June 30, 2020. AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
This is to inform you that Quarterly Conference Call for the Investors and Analysts has been scheduled on Monday, July 27, 2020 at 3:00 PM IST to discuss the Company's Q1 FY21 Results. AARTI DRUGS LTD. - 524348 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we inform you that the Company has received information from Link Intime India Private Limited, Registrar & Share Transfer Agent of the Company for Loss of share certificates.